DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Low dose of Micardis® (Drug); Medium dose of Micardis® (Drug); High dose of Micardis® (Drug); Hydrochlorothiazide (Drug); Placebo (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

Primary: To identify doses of Micardis®(telmisartan) which, administered once daily, are more effective than placebo and not inferior to HCTZ in lowering systolic blood pressure (SBP) in patients with isolated systolic hypertension (ISH), and to assess the dose response relationship of the antihypertensive effect of telmisartan over the dose range of 20 to 80 mg. Secondary: Target fall in SBP, change from baseline in seated DBP. Safety and tolerability of Micardis® and HCTZ in patients with ISH as measured by changes in physical examinations, heart rate, laboratory parameters and/or 12-lead ECG, as well as the incidence and severity of adverse events.

Clinical Details

Official title: A Randomised, Double- Blind, Placebo-controlled, 6 Week Parallel-group Trial on the Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily) or Hydrochlorothiazide 12.5 mg p.o. Once Daily in the Management of Patients With Isolated Systolic Hypertension (ISH). (ARAMIS - Study = Angiotensin II Receptor Antagonist Micardis in Isolated Systolic Hypertension)

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome:

Change from baseline in seated systolic blood pressure at trough (24 hours post-dose)

Change from baseline in urine albumine excretion rate

Change from baseline in pulse wave velocity

Secondary outcome:

Percentage of patients achieving a target fall in SBP

Changes in seated diastolic blood pressure (DBP)

Change from baseline in augmentation index

Incidence and intensity of adverse events

Number of patients with relevant changes from baseline in physical examination

Number of patients with relevant changes in Heart Rate (HR)

Number of patients with relevant changes in laboratory parameters

Number of patients with relevant changes in 12-lead electrocardiogram (ECG)

Eligibility

Minimum age: 35 Years. Maximum age: 84 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- At least 35 years, but less than 85 years of age

- Mean SBP ≥ 150 mm Hg and mean DBP < 90 mm Hg at the randomisation visit (visit 2),

according to WHO definitions of ISH (excluding the subgroup of borderline ISH)

- Hypertensive patients not on current antihypertensive therapy or able to stop current

treatment for a period of up to 8 - 10 weeks without endangering the health of the

patient (investigator's discretion)

- Ability to provide written informed consent

Exclusion Criteria:

- Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in period)

who: 1. are not surgically sterile; and/or 2. are nursing 3. are of child-bearing potential and are not practicing acceptable means of birth control or do NOT plan to continue using this method throughout the study. Acceptable methods of birth control include oral, implantable or injectable contraceptives

- Mean systolic blood pressure ≥ 180 mmHg at the randomization Visit 2

- Known or suspected secondary hypertension

- Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

1. Serum glutamic pyruvate transaminase (ALT) or serum glutamic oxaloacetic transaminase (AST) > than 2 times the upper limit of normal range 2. Serum creatinine > or 1. 8 mg/dl (or 159 µmol/l)

- Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients

post-renal transplant or with only one functioning kidney

- Clinically relevant hypokalemia or hyperkalemia

- Uncorrected volume or sodium depletion

- Primary aldosteronism

- Hereditary fructose intolerance

- Biliary obstructive disorders

- Symptomatic congestive heart failure

- Angina pectoris or previous myocardial infarction

- Previous percutaneous transluminal coronary angioplasty or coronary artery bypass

craft

- Previous cerebrovascular accident or hypertensive encephalopathy or transient

ischemic attack(s)

- Current treatment with any antihypertensive agents, whether or not prescribed for

this indication, that cannot be safely stopped (investigators decision) by the start of the run-in period. Any pre-treatment with diuretics, ACE inhibitors or angiotensin II receptor antagonists requires an extension of the run-in period from 2 to 4 weeks for adequate wash-out

- Atrial fibrillation (controlled or otherwise) or any other clinically relevant

cardiac arrhythmias as determined by the clinical investigator

- Hemodynamically relevant aortic or mitral valve stenosis, obstructive hypertrophic

cardiomyopathy or other outflow obstruction of the left ventricle

- Patients with non-insulin-dependent diabetes mellitus requiring treatment with oral

hypoglycemics who fail to meet the following criteria by history: 1. Fasting blood glucose less than 200 mg/dl (11. 1 mmol/l) 2. Therapy stabilized for at least one month prior to start of placebo run-period

- Patients with diabetes mellitus requiring treatment with insulin

- Patients who have previously experienced symptoms characteristics of angioedema

during treatment with ACE inhibitors or angiotensin II receptor antagonists

- Known drug or alcohol dependency

- Any investigational therapy within one month of signing the informed consent form and

during the trial

- Known hypersensitivity to any component of the formulation of telmisartan or

hydrochlorothiazide including allergy to sulfonamides

- Concomitant use of lithium or cholestyramine or colestipol resins (potential drug

interactions with HCTZ)

- Gout (contraindication for treatment with HCTZ)

- Any other clinical condition which, in the opinion of the principal investigator,

would not allow safe completion of the protocol and safe administration of telmisartan or hydrochlorothiazide

Locations and Contacts

Additional Information

Starting date: October 1999
Last updated: July 7, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017